Barclays
MAZE

Barclays’s Maze Therapeutics MAZE Stock Holding History

Barclays’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$276K Sell
9,262
-30,246
-77% -$1.33M ﹤0.01% 3513
2025
Q4 		$1.64M Buy
39,508
+11,992
+44% +$412K ﹤0.01% 3075
2025
Q3 		$713K Buy
27,516
+12,875
+88% +$217K ﹤0.01% 3586
2025
Q2 		$180K Sell
14,641
-3
-0% -$31 ﹤0.01% 4341
2025
Q1 		$161K Buy
+14,644
New +$176K ﹤0.01% 4162

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's MAZE Position: Q1 2026 in Review

Barclays reduced its Maze Therapeutics (MAZE) stake by 77% in Q1 2026, selling an estimated $1.33M and leaving 9,262 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

Barclays first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.64M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Barclays held 9,262 shares of Maze Therapeutics worth $276K as of Q1 2026.
  • Barclays sold 30,246 Maze Therapeutics shares in Q1 2026, an estimated $1.33M.
  • Maze Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3513 holding.
  • Barclays first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Barclays's Maze Therapeutics position peaked at $1.64M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.